Literature DB >> 8025760

Opportunistic infection during treatment with low dose methotrexate.

G P LeMense1, S A Sahn.   

Abstract

Two patients receiving low dose methotrexate, one with rheumatoid arthritis and the other with pityriasis rubra pilaris, developed disseminated histoplasmosis and Mycobacterium avium intracellulare pneumonia, respectively. Twenty-three cases of opportunistic infection in patients receiving low dose methotrexate have been reported previously, with Pneumocystis carinii pneumonia being the most common infection (10 of 23, 43%). Patients receiving low dose methotrexate are at risk for opportunistic infection despite normal leukocyte counts.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8025760     DOI： 10.1164/ajrccm.150.1.8025760

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


  18 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

2.  Pulmonary coinfection by Pneumocystis carinii and Aspegillus fumigatus in a seronegative arthritis patient treated with low-dose methotrexate.

Authors:  M Mariñosa; A Soler; X Nogués; J Pedro-Botet
Journal:  Clin Rheumatol       Date:  2004-12       Impact factor: 2.980

3.  Articular presentation of disseminated histoplasmosis.

Authors:  Debajit Sen; Jonathan Birns; Anisur Rahman
Journal:  Clin Rheumatol       Date:  2006-05-25       Impact factor: 2.980

Review 4.  Methotrexate-induced pulmonary toxicity in psoriatic arthritis (PsA): case presentation and literature review.

Authors:  Federico Rondon; Odilio Mendez; Nestor Spinel; Carlos Ochoa; Cristian Saavedra; Edgar Penaranda; Ignacio Garcia-Valladares; Luis R Espinoza; Antonio Iglesias-Gamarra
Journal:  Clin Rheumatol       Date:  2011-05-26       Impact factor: 2.980

5.  A Case of Disseminated Histoplasmosis in a Patient with Rheumatoid Arthritis on Abatacept.

Authors:  Nina Jain; Jeffrey B Doyon; Jacob E Lazarus; Inga-Marie Schaefer; Melanie E Johncilla; Agoston T Agoston; Anuj K Dalal; Gustavo E Velásquez
Journal:  J Gen Intern Med       Date:  2018-03-12       Impact factor: 5.128

Review 6.  [Pneumocystis jiroveci pneumonia (PcP) in patients with rheumatic diseases: case report and review].

Authors:  B Bertisch; C Ruef
Journal:  Z Rheumatol       Date:  2006-02       Impact factor: 1.372

7.  Disseminated histoplasmosis successfully treated with liposomal amphotericin B following azathioprine therapy in a patient from a nonendemic area.

Authors:  F Poveda; J García-Alegría; M A de las Nieves; E Villar; N Montiel; A del Arco
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-05       Impact factor: 3.267

8.  Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus.

Authors:  Ratchaya Lertnawapan; Kitti Totemchokchyakarn; Kanokrat Nantiruj; Suchela Janwityanujit
Journal:  Rheumatol Int       Date:  2008-09-25       Impact factor: 2.631

9.  Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.

Authors:  J D Greenberg; G Reed; J M Kremer; E Tindall; A Kavanaugh; C Zheng; W Bishai; M C Hochberg
Journal:  Ann Rheum Dis       Date:  2009-04-08       Impact factor: 19.103

10.  TNF-α Antagonist and Infection in Rheumatoid Arthritis.

Authors:  Julia F Simard; Murray A Mittleman; Nancy A Shadick; Elizabeth W Karlson
Journal:  Open J Rheumatol Autoimmune Dis       Date:  2012-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.